Fluid Intelligence Partially Mediates the Effect of Working Memory on Speech Recognition in Noise.

Purpose: Although the existing literature has explored the link between cognitive functioning and speech recognition in noise, the specific role of fluid intelligence still needs to be studied. Given the established association between working memory capacity (WMC) and fluid intelligence and the predictive power of WMC for speech recognition in noise, we aimed to elucidate the mediating role of fluid intelligence.

Method: We used data from the n200 study, a longitudinal investigation into aging, hearing ability, and cognitive functioning.

16p11.2 Deletion Syndrome.

16p11.2 deletion syndrome is a rare genetic abnormality that affects an individual's cognitive abilities. 16p11.

Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR): Cytogenetic Abnormalities and Gene Mutations.

Acute myeloid leukemia, myelodysplasia-related (AML-MR) is a particularly aggressive and adverse subtype of acute myeloid leukemia, predominantly affecting older adults who often face complex treatment challenges and poor prognoses. The majority of AML-MR patients fail to achieve remission, leading to significantly reduced overall survival rates. In light of these dire outcomes, staying informed about the most recent advancements in AML-MR research and clinical practice is imperative.

An MDS Patient with Deletion 20q and a t(9;22)(q34;q11.2): A Case Report and Review of the Literature.

We report a 76-year-old male patient with myelodysplastic syndrome (MDS) with a t(9;22) and deletion 20q only by FISH. Past medical history is significant for prostate cancer status post radiation therapy and a 28-pack-year smoking history. In 2016, the patient developed a DVT and incidentally was found to have a BCR::ABL1 (p210) by PCR analysis (level of 0.

Novel Immunotherapy Targets for Relapsed/Refractory B-ALL: A Literature Review.

B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent cancer in United States children. In recent years, immunotherapies using chimeric antigen receptors (CAR T-cells) have improved prognosis for patients with B-ALL. Previous CAR T therapies have used CD19 as a target, but loss of this protein through antigen escape may cause relapse with slim chance of remission.